(52 days)
The Cardiac STATus™ CK-MB/Myoglobin Rapid One Step Test is intended for use as an in vitro diagnostic product for the rapid qualitative determination of CK-MB and myoglobin in serum, human whole blood, or plasma as an aid in the diagnosis of myocardial infarction in emergency room, critical care, point of care or hospital settings.
Not Found
This looks like a medical device approval letter. I will do my best to extract the information you requested, but please note that due to the specialized nature of the document, some of the requested information might not be present or explicitly stated.
Based on the provided text, here's an analysis of the acceptance criteria and study information for the "Cardiac STATus CK-MB/Myoglobin Rapid One-Step Test":
No explicit acceptance criteria or detailed study results are provided in this document. This document is a 510(k) clearance letter from the FDA, indicating that the device has been found substantially equivalent to a legally marketed predicate device. It does not typically contain the detailed performance study results or specific acceptance criteria that would have been submitted by the manufacturer.
However, I can infer some aspects based on the nature of a 510(k) submission for an in vitro diagnostic device:
-
A table of acceptance criteria and the reported device performance:
- No specific acceptance criteria or reported device performance metrics (e.g., sensitivity, specificity, accuracy against a gold standard) are explicitly stated in this document. Such information would be detailed in the manufacturer's 510(k) submission, not typically in the FDA clearance letter itself.
- Inferred based on the indication for use: As an "in vitro diagnostic product for the rapid qualitative determination of CK-MB and myoglobin... as an aid in the diagnosis of myocardial infarction," the device would have been evaluated for its ability to accurately detect the presence or absence of CK-MB and myoglobin, implying performance metrics like sensitivity, specificity, and potentially concordance with a reference method.
-
Sample sized used for the test set and the data provenance:
- Not specified in this document.
-
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Not specified in this document. For a diagnostic test like this, the "ground truth" for myocardial infarction would likely be established by clinical diagnosis, potentially involving multiple clinical factors and other diagnostic tests, rather than solely by a panel of experts reviewing the device's output.
-
Adjudication method for the test set:
- Not specified in this document.
-
If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- Not applicable. This device is an in vitro diagnostic test kit (a rapid one-step test for biochemical markers), not an AI-assisted diagnostic tool that humans would use to interpret images or other data. Therefore, an MRMC study comparing human readers with and without AI assistance would not be relevant.
-
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- Yes, implicitly. As an in vitro diagnostic assay, its performance is evaluated as a standalone product. The "test" itself generates the result. While a healthcare professional interprets the result in the context of a patient's overall clinical picture, the assay's performance characteristics (e.g., how accurately it detects the markers) are determined independently of human interpretation of its internal workings. The product is described as a "Rapid One-Step Test," suggesting it provides a direct qualitative result (e.g., positive/negative line on a strip).
-
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- Not explicitly stated in this document. For a device "as an aid in the diagnosis of myocardial infarction," the ground truth for the clinical studies would typically involve:
- Clinical diagnosis of MI: Based on a combination of clinical symptoms, ECG changes, and serial cardiac marker measurements (often using a laboratory-based, well-established reference method).
- Reference method comparison: The device's CK-MB and Myoglobin results would be compared against established laboratory methods for these markers.
- Not explicitly stated in this document. For a device "as an aid in the diagnosis of myocardial infarction," the ground truth for the clinical studies would typically involve:
-
The sample size for the training set:
- Not specified in this document. (Training sets are relevant for developing the assay, but the 510(k) primarily focuses on clinical validation.)
-
How the ground truth for the training set was established:
- Not specified in this document. Similar to the test set, it would likely involve clinical diagnosis and comparison to reference laboratory methods during the development phase.
In summary, this FDA 510(k) clearance letter provides high-level information about the regulatory approval of the "Cardiac STATus CK-MB/Myoglobin Rapid One-Step Test" but does not contain the detailed study specifics (acceptance criteria, sample sizes, expert qualifications, ground truth methods, or performance metrics) typically found in the clinical study report itself. These details would have been part of the original 510(k) submission.
§ 862.1215 Creatine phosphokinase/creatine kinase or isoenzymes test system.
(a)
Identification. A creatine phosphokinase/creatine kinase or isoenzymes test system is a device intended to measure the activity of the enzyme creatine phosphokinase or its isoenzymes (a group of enzymes with similar biological activity) in plasma and serum. Measurements of creatine phosphokinase and its isoenzymes are used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy.(b)
Classification. Class II.